

DAFTAR PUSTAKA

1. Humbert M, Galiè N, Rubin LJ, Simonneau G, McLaughlin V V. The Seventh World Symposium on Pulmonary Hypertension: our journey to Barcelona. *European Respiratory Journal*. European Respiratory Society; 2024; 64 (1): 1-22
2. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *European Heart Journal*. Oxford University Press; 2022; 43 (1): 3618–731.
3. Dinarti LK, Hartopo AB, Kusuma AD, Satwiko MG, Hadwiono MR, Pradana AD, et al. The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: A descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. *BMC Cardiovasc Disord*. 2020;20(1). 1-17
4. Raihani MS, Yanni M, Asri E, Elfi EF, Kurnia D. Gambaran Karakteristik Pasien Hipertensi Arteri Pulmonal Di Rsup Dr. M. Djamil Padang Tahun 2017-2021. 2022: 1-22
5. Guignabert C, Aman J, Bonnet S, Dorfmueller P, Olschewski AJ, Pullamsetti S, et al. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. In: *European Respiratory Journal*. European Respiratory Society; 2024: 1-14
6. Humbert M, Guignabert C, Bonnet S, Dorfmueller P, Klinger JR, Nicolls MR, et al. Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives. *European Respiratory Journal*. European Respiratory Society; 2019. 53 (1): 1-18
7. Sysol JR, Machado RF. Classification and pathophysiology of pulmonary hypertension. *Continuing Cardiology Education*. 2018;4(2):2–12.
8. Tello K, Seeger W, Naeije R, Vanderpool R, Ghofrani HA, Richter M, et al. Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. *British Journal of Pharmacology*. John Wiley and Sons Inc; 2021;178(1):90–107.
9. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. *Circulation*. 2008; 117(1): 1436–48.
10. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, et al. Right heart adaptation to pulmonary arterial hypertension: Physiology and pathobiology. *Journal of the American College of Cardiology*. 2013. 1-33
11. Ro SK, Sato K, Ijuin S, Sela D, Fior G, Heinsar S, et al. Assessment and diagnosis of right ventricular failure—retrospection and future directions. *Frontiers in Cardiovascular Medicine*. Frontiers Media S.A.; 2023; 10(1): 3-23
12. Rajiah PS, Kalisz K, Broncano J, Goerne H, Collins JD, François CJ, et al. Myocardial Strain Evaluation with Cardiovascular MRI: Physics, Principles, and Clinical Applications. *Radiographics*. 2022;42(1):968–90.
13. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography. Endorsed by the European Association of Echocardiography, a registered branch of the

- European Society of Cardiology, and the Canadian Society of Echocardiography. *Journal of the American Society of Echocardiography*. 2010; 23(1): 685–713.
14. Blessberger H, Binder T. Two dimensional speckle tracking echocardiography: Basic principles. *Heart*. 2010;96 (1):716–22.
 15. Anderson K, Ducharme A. Markers and Correlates of Right Ventricular Function with Computed Tomography, Echocardiography, and Magnetic Resonance. In: *Biomarkers in Cardiovascular Disease*. Springer Netherlands; 2015. 1–38.
 16. Sciatti E, Merlo A, Scangiuzzi C, Limonta R, Gori M, D’Elia E, et al. Prognostic Value of sST2 in Heart Failure. *Journal of Clinical Medicine*. Multidisciplinary Digital Publishing Institute (MDPI); 2023; 12(1): 221-225
 17. Dudek M, Kałużna-Oleksy M, Migaj J, Sawczak F, Krysztofiak H, Lesiak M, et al. sST2 and Heart Failure—Clinical Utility and Prognosis. *J Clin Med*. 2023;12(1) :12-21
 18. Ye H, Wu Q, Zhang N, Shi J, Zhang H, Wang Q, et al. The prognostic value of sST2 in connective tissue disease patients with pulmonary hypertension. *Rheumatology (United Kingdom)*. 2022;61(2):3989–96.
 19. Zhang T, Xu C, Zhao R, Cao Z. Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis. *Frontiers in Cardiovascular Medicine*. Frontiers Media S.A. 2021; 8 (1): 1-11
 20. Aimo A, Januzzi JL, Bayes-Genis A, Vergaro G, Sciarrone P, Passino C, et al. Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. *Journal of the American College of Cardiology*. Elsevier USA; 2019. 74(2): 2193–203.
 21. Kovacs G, Bartolome S, Denton CP, Gatzoulis MA, Gu S, Khanna D, et al. Definition, classification and diagnosis of pulmonary hypertension. *European Respiratory Journal*. European Respiratory Society; 2024. 1-14
 22. Condliffe R. Pulmonary arterial hypertension associated with congenital heart disease: classification and pathophysiology. *Journal of Congenital Cardiology*. 2020;4(1):1-18
 23. Ferrero P, Constantine A, Chessa M, Dimopoulos K. Pulmonary arterial hypertension related to congenital heart disease with a left-to-right shunt: phenotypic spectrum and approach to management. *Frontiers in Cardiovascular Medicine*. Frontiers Media SA; 2024; 11 (1) :1-16
 24. Lan NSH, Massam BD, Kulkarni SS, Lang CC. Pulmonary Arterial Hypertension: Pathophysiology and Treatment. *Diseases*. 2018;6(1):38-46
 25. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: Pathogenesis and clinical management. *BMJ (Online)*. BMJ Publishing Group; 2018; 360(2): 122-32
 26. Sharifi Kia D, Kim K, Simon MA. Current Understanding of the Right Ventricle Structure and Function in Pulmonary Arterial Hypertension. *Frontiers in Physiology*. Frontiers Media S.A.2021.12(1): 1-25
 27. Maron BA, Kovacs G, Vaidya A, Bhatt DL, Nishimura RA, Mak S, et al. Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week. *Journal of the American College of Cardiology*. Elsevier Inc.; 2020; 76 (1): 2671–81.
 28. Dodson MW, Brown LM, Elliott CG. Pulmonary Arterial Hypertension. *Heart Failure Clinics*. Elsevier Inc. 2018;14 (1): 255–69.

29. Rafikova O, Al Ghouleh I, Rafikov R. Focus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development. Antioxidants and Redox Signaling. Mary Ann Liebert Inc. 2019;31(1) : 933–53.
30. Hemnes A, Rothman AMK, Swift AJ, Zisman LS. Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. Pulm Circ. 2020;10.
31. Sanz J, Sánchez-Quintana D, Bossone E, Bogaard HJ, Naeije R. Anatomy, Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review. Journal of the American College of Cardiology. Elsevier USA. 2019; 73 (1): 1463–82.
32. Wu CC, Takeuchi M. Echocardiographic assessment of right ventricular systolic function. Cardiovascular Diagnosis and Therapy. AME Publishing Company; 2018. 8(1): 70–9.
33. Hameed A, Condliffe R, Swift AJ, Alabed S, Kiely DG, Charalampopoulos A. Assessment of Right Ventricular Function—a State of the Art. Current Heart Failure Reports. Springer; 2023. 20 (1): 194–207.
34. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. Journal of the American Society of Echocardiography. 2019;32(2):1–64.
35. Mukherjee M, Rudski LG, Addetia K, Afalalo J, D'Alto M, Freed BH, et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography. Journal of the American Society of Echocardiography. 2025;38(2):141–86.
36. Jang AY, Shin MS. Echocardiographic screening methods for pulmonary hypertension: A practical review. Journal of Cardiovascular Imaging. Korean Society of Echocardiography; 2020. 28(1):1–9.
37. Sheehan F, Redington A. The right ventricle: Anatomy, physiology and clinical imaging. Heart. 2008; 94(1):1510–5.
38. Truong U, Meinel K, Haddad F, Koestenberger M, Carlsen J, Ivy D, et al. Update on noninvasive imaging of right ventricle dysfunction in pulmonary hypertension. Cardiovascular Diagnosis and Therapy. AME Publishing Company; 2020; 10(1): 1604–24.
39. Rajagopal S, Bogaard HJ, Elbaz MSM, Freed BH, Remy-Jardin M, van Beek EJR, et al. Emerging multimodality imaging techniques for the pulmonary circulation. European Respiratory Journal. European Respiratory Society; 2024. 1-34
40. Ayach B, Fine NM, Rudski LG. Right ventricular strain: Measurement and clinical application. Current Opinion in Cardiology. Lippincott Williams and Wilkins; 2018; 33(1): 486–92.
41. Bansal M, Kasliwal RR. How do i do it? Speckle-tracking echocardiography. Indian Heart Journal. Elsevier B.V. 2013; 65 (1): 117–23.
42. Prieto O, Cianciulli TF, Stewart-Harris A, Rodriguez A, Saccheri MC, Lax JA, et al. Speckle tracking imaging in patients with pulmonary hypertension. J Cardiovasc Imaging. 2021;29(2):236–51.

43. Haeck ML, Scherptong RW, Marsan NA, Holman ER, SchaliJ MJ, Bax JJ. Prognostic value of right ventricular longitudinal peak systolic strain in patients with pulmonary hypertension. 2012;5(2):628–36.
44. Tadic M, Nita N, Schneider L, Kersten J, Buckert D, Gonska B, et al. The Predictive Value of Right Ventricular Longitudinal Strain in Pulmonary Hypertension, Heart Failure, and Valvular Diseases. Vol. 8, *Frontiers in Cardiovascular Medicine*. Frontiers Media SA; 2021: 1-14
45. Roflin E, Liberty IA, Pariyana. *Populasi, Sampel, Variabel Dalam Penelitian Kedokteran*. Nasya Expanding Management; 2021 (1): 25-8
46. Ingram D, Alamri AK, Penn BA, Mayeux JD, Ma CL, Clapham KR, et al. Characteristics of Patients With Pulmonary Arterial Hypertension in a Pulmonary Hypertension Association-Accredited Comprehensive Care Center: A Contrast in Features When Compared With US National Registry Data. *Cureus*. 2022; 1-19
47. Harikrishnan S, Mani A, G S, M A, Menon J, G R, et al. Pulmonary Hypertension Registry of Kerala, India (PRO-KERALA): One-year outcomes. *Indian Heart J*. 2022;74:34–9.
48. Küçükoglu SM, Kaymaz C, Alehan D, Kula S, Akcevin A, Celiker A, et al. Pulmonary arterial hypertension associated with congenital heart disease: lessons learnt from the large Turkish Nationwide Registry (THALES). *Pulm Circ*. 2021;11. 1-22
49. Saputra F, Hartopo AB, Hariawan H, Anggrahini DW, Kris Dinarti L. Association between serum soluble ST2 level and right ventricle systolic function on pulmonary hypertension due to atrial septal defect. *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)*. 2020;52. 1-16
50. Farber HW, Chakinala MM, Cho M, Frantz RP, Frick A, Lancaster L, et al. Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real-world patient data repository. *Pulm Circ*. 2023;13(1). 1-12
51. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: a review. *Molecules*. 2013; 18 (1) : 15314–28.
52. Yan L, Shi W, Liu Z, Zhao Z, Luo Q, Zhao Q, et al. The benefit of exercise-based rehabilitation programs in patients with pulmonary hypertension: a systematic review and meta-analysis of randomized controlled trials. *Pulm Circ*. 2021;11(2). 1-27
53. Toma M, Savonitto G, Lombardi CM, Airò E, Driussi M, Gentile P, et al. Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype. *Clinical Research in Cardiology*. 2025;114:215–26.
54. Martin SS, Shapiro EP, Mukherjee M. Atrial septal defects – Clinical manifestations, echo assessment, and intervention. *Clinical Medicine Insights: Cardiology*. Libertas Academica Ltd..2015; 8 (1): 93–8.
55. Prisco S, Lenzini L, Vanderriele PE, Torresan F, Maiolino G, Iacobone M, et al. The Role Of Aldosterone And Angiotensin Ii In The Regulation Of Parathormone Secretion At1 And Gper-1 Heterodimerization Potentiates Cyp11b2 Gene Expression In Aldosterone Producing Adenoma Cardiac Remodelling In Renal Transplanted Patients: A Question Of Gender? *Journal of Hypertension*. 2018. 36(1): 1-32

56. Bokma JP, Winter MW, Kornaat EM, Vliegen HW, Dijk AP, Melle JP. Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system (REDEFINE) trial: Rationale and design of a randomized, double-blind, placebo-controlled clinical trial. 2017;186:83–90.
57. Maron BA, Kovacs G, Vaidya A, Bhatt DL, Nishimura RA, Mak S, et al. Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week. *Journal of the American College of Cardiology*. Elsevier Inc.; 2020; 76(1): 2671–81.
58. Geenen LW, Baggen VJM, Kauling RM, Koudstaal T, Boomars KA, Boersma E, et al. The prognostic value of soluble ST2 in adults with pulmonary hypertension. *J Clin Med*. 2019;8(1): 1-11
59. Yaghi S, Novikov A, Trandafirescu T. Clinical update on pulmonary hypertension. *Journal of Investigative Medicine*. BMJ Publishing Group; 2020; 68(1): 821–7.
60. Weatherald J, Fleming TR, Wilkins MR, Cascino TM, Psotka MA, Zamanian R, et al. Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension. *European Respiratory Journal*. European Respiratory Society; 2024: 1-32
61. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(2):1–39.
62. Zheng YG, Yang T, He JG, Chen G, Liu ZH, Xiong CM, et al. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. *Clin Cardiol*. 2014;37(2):365–70.
63. Chida A, Sato H, Shintani M, Nakayama T, Kawamura Y, Furutani Y, et al. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination: Useful biomarker for predicting outcome of childhood pulmonary arterial hypertension. *Circulation Journal*. 2014;78(2):436–42.
64. Agoston-Coldea L, Lupu S, Petrovai D, Mocan T, Mousseaux E. Correlations between echocardiographic parameters of right ventricular dysfunction and galectin-3 in patients with chronic obstructive pulmonary disease and pulmonary hypertension. *Med Ultrason*. 2015;17(2):487–95.
65. Rabkin SW, Tang JKK. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. *Heart Failure Reviews*. Springer; 2021; 26(1): 799–812.
66. Keranov S, Widmann L, Jafari L, Liebetrau C, Keller T, Troidl C, et al. GDF-15 and soluble ST2 as biomarkers of right ventricular dysfunction in pulmonary hypertension. *Biomark Med*. 2022;16(2):1193–207.
67. Banaszkiwicz M, Gąsecka A, Darocha S, Florczyk M, Pietrasik A, Kędzierski P, et al. Circulating Blood-Based Biomarkers in Pulmonary Hypertension. *Journal of Clinical Medicine*. MDPI. 2022; 11(1) : 1-14
68. Shah R V., Chen-Tournoux AA, Picard MH, Van Kimmenade RRJ, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. *Circ Heart Fail*. 2009;2(2):311–9.

69. Yan L, Zhao Z, Zhao Q, Jin Q, Zhang Y, Li X, et al. The clinical characteristics of patients with pulmonary hypertension combined with obstructive sleep apnoea. *BMC Pulm Med.* 2021;21(1): 23-36
70. Luk KS, Ip C, Gong MQ, Wong SH, Wu WKK, Dong M, et al. A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension. *Journal of Geriatric Cardiology.* Science Press. 2017; 14(1): 766–71.
71. Pratama RS, Hartopo AB, Anggrahini DW, Dewanto VC, Dinarti LK. Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect. *Pulm Circ.* 2020;10(1): 1-11.
72. Banaszkiwicz M, Pietrasik A, Darocha S, Piłka M, Florczyk M, Dobosiewicz A, et al. Soluble ST2 protein as a new biomarker in patients with precapillary pulmonary hypertension. *Archives of Medical Science.* 2024;20(2):1442–51
73. Wagner A, Köhm M, Nordin A, Svenungsson E, Pfeilschifter JM, Radeke HH. Increased Serum Levels of the IL-33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis. *Scand J Immunol.* 2015;82(1):269–74

